TITLE

Effect of CYP2C19 variants on clopidogrel

AUTHOR(S)
Kuritzky, Louis
PUB. DATE
November 2009
SOURCE
Primary Care Reports;Nov2009 Primary Care, p21
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome affect antiplatelet activity of CPG.
ACCESSION #
45829608

 

Related Articles

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Oncology Alert;Nov2009 Supplement, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Cardiology Alert;Nov2009 Clinical Briefs, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Neurology Alert;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers. Kwon-Duk Seo; Young Dae Kim; Young-Won Yoon; Jong-Youn Kim; Kyung-Yul Lee // Yonsei Medical Journal;May2014, Vol. 55 Issue 3, p683 

    Purpose: Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) system into its active thiol metabolite. CYP3A4 is involved in the metabolism of both clopidogrel and dihydropyridine calcium channel blockers (CCBs). A few reports have suggested an inhibitory interaction between CCBs and...

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Scott, S. A.; Sangkuhl, K.; Gardner, E. E.; Stein, C. M.; Hulot, J.-S.; Johnson, J. A.; Roden, D. M.; Klein, T. E.; Shuldiner, A. R. // Clinical Pharmacology & Therapeutics;Aug2011, Vol. 90 Issue 2, p328 

    The article discusses the implementation of consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. It mentions the aim of the guidelines which is to provide information regarding the clinical use of CYP2C19 genotype test results in patients requiring...

  • The role of genetic factors in clopidogrel antiplatelet therapy. Cieślewicz, Artur Robert; Kaźmierczak, Ewa; Jabłecka, Anna // Advances in Interventional Cardiology;2012, Vol. 8 Issue 2, p126 

    Thienopyridine derivative antiplatelet agents play an important role in the treatment of coronary artery disease. Clopidogrel is a drug blocking action of the platelet ADP receptor (P2Y12). It is applied in the form of a prodrug that requires metabolic activation by cytochrome P450 enzymes. The...

  • CYP2C19 Genotype-Guided Antiplatelet Therapy in a Patient with Clopidogrel Resistance. Rai, Mridula; Seip, Richard L.; Gupta, Ankur; McKay, Raymond G.; Hirst, Jeffrey; Thompson, Paul D.; Ruaño, Gualberto // Connecticut Medicine;May2012, Vol. 76 Issue 5, p267 

    We report a switch in antiplatelet medication based on platelet function and CYP2C19 genotype test results in a 74-year-old man with severe coronary arterial disease. Upon bare metal stent implantation at age 66, clopidogrel therapy (75 mg/day) was initiated to supplement aspirin. Over the next...

  • SHORT CUTS. Fister, Kristina // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p536 

    This section discusses various health-related studies published in different journals. A study published in the "New England Journal of Medicine" estimated the cumulative doses of radiation received by patients in the U.S. during imaging procedures. Another study published in the same journal...

  • Progress of Antiplatelet Pharmacogenomics. Oestreich, Julie H. // Current Drug Targets;Nov2011, Vol. 12 Issue 12, p1848 

    Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics